Rheumatologe

Blog von Dr. med. Lothar M. Kirsch / 祁建德 // Poetry / Travels / Languages / Rheumatic Diseases / Tea

Seiten / Pages

▼
Showing posts with label DMARDs. Show all posts
Showing posts with label DMARDs. Show all posts
Friday, June 19, 2020

Iguratimod at the EULAR 2020 Online Meeting

›
Since 2012 I've been looking at iguratimod [1]. Iguratimod is a conventional synthetic disease modifying anti-rheumatic drug (c...
Monday, May 25, 2020

Biologika und Biosimilars 2020

›
Biologika werden seit über 20 Jahren in der Rheumatologie eingesetzt. Es kommen laufend neue hinzu. Durch Biosimilars wird versucht d...
Thursday, March 8, 2018

Bimekizumab at the 2017 ACR Annual Meeting in San Diego

›
Bimekizumab (alternative names: CDP-4940 and UCB-4940) is a monoclonal antibody that targets IL-17A and IL-17F. Bimekizumab is deve...

Guselkumab at the 2017 ACR Annual Meeting in San Diego

›
Guselkumab is a monoclonal antibody that targets the p19 subunit of IL-23. Guselkumab is marketed by Janssen-Cilag under the name...

Risankizumab at the 2017 ACR Annual Meeting in San Diego

›
Risankizumab is a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit. It...
›
Home
View web version

Über mich / About myself / 自己的介绍

Rheumatologe
View my complete profile
Powered by Blogger.